ProCE Banner Series

TROP-2–Targeted ADCs for NSCLC: Integrating a New Therapeutic Option

Don't miss your chance to be at the forefront of lung cancer therapeutics! Interact with experts as they review the latest clinical evidence and discuss the benefits and nuances of incorporating TROP-2–targeted ADCs into the care of patients with advanced NSCLC.

ELCC 2024 Industry Satellite Symposium

  AMA
Who Should Attend

This program is intended for oncologists, researchers, and other healthcare professionals caring for patients with non-small-cell lung cancer.

All Events

TROP-2–Targeted ADCs for NSCLC: Integrating a New Therapeutic Option

Past Events

March

20

2024

6:15 PM - 7:45 PM Central European Time (CET)

In-personVirtual

Prague Congress Centre, 5. května 1640/65, Nusle, 140 00 Prague 4, Czech Republic

Faculty

ProCE Banner Faculty
Luis Paz-Ares, MD, PhD

Chair of the Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor
Universidad Complutense de Madrid
Head of the Lung Cancer Unit
CNIO (Spanish National Cancer Research Center)
Madrid, Spain

ProCE Banner Faculty
David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Paris-Saclay University
International Center for Thoracic Cancers
Villejuif, France

ProCE Banner Faculty
Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Topics

  • Welcome and Introduction
  • Role of TROP-2 in NSCLC
  • Latest Therapeutic Advancements in Targeting TROP-2 in NSCLC
  • Contemplating the Future Role of Targeting TROP-2 in NSCLC
  • Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Target Audience
This program is intended for oncologists, researchers, and other healthcare professionals caring for patients with non-small-cell lung cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the biological rationale for targeting TROP-2 and features that differentiate the ADCs targeting TROP-2
  • Select patients with NSCLC for treatment with TROP-2 targeting ADCs that aligns with the eligibility criteria of the major studies and is personalized for optimal outcome 
  • Develop monitoring (including early identification), management (including prophylaxis), and supportive care plans to limit treatment-related adverse events associated with TROP-2–directed ADCs 
  • Evaluate the rationale for combination strategies with TROP-2–targeting ADCs and the clinical trials of TROP-2–targeting combinations in various NSCLC disease settings
  • Offer participation in clinical trials of investigational TROP-2–targeting ADCs as part of therapeutic strategies for eligible patients with NSCLC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Gilead Sciences, Inc.